Correction started in the region ... ?

Jakarta Stock exchange index drop almost 200 points from it peak. In fact the index had touched the mid term moving average. A not so good sign moving forward.
STI, PHI, TSE, KLSE seems holding well above the 50 days moving average, but a further drop will see a major correction in the making ..

Next up wave started ...

For the past 1 week, it seems the up wave had just begins, some small cap had made a significant 20% upward within these few days ... more are moving now ..

Identify a shooting star ...

Out of thousand over companies, it remains a challenge to catch a shooting star in the mist. A shooting star is one stock that will run regarless how is the index perform and most of the time they will out perform the market by many folds. Eg 3A, this stock price at 0.10 cent on sep06 shoot up to 0.43 cent by Jul07, then up and down within 0.25 to 0.40 from Jul 07 til Jul 09. From Aug09 til Oct09, the share price went up from 0.43 to 1.67, a whooping abt 250% return in 2 months.
My best past performer was Insas-W, from 0.135 , sold 0.425, 203% return ..

Currently, am holding a few porfolio which I hope will spearhead againt the market soon. This are infact "gems" that are not to be missed in this up cycle ...

Major correction around corner ?

How to identify if there is a major correction around the corner ? On analysis part, most down turn occur preceded with unusual high volumn. On that note, current volumn is relatively low. Having say that, there is no doubt some counter had in fact trend down even before the KLSE. As such, need to monitor and evaluate overall piture before get trap in a bear downturn.

The swine flu opportunity ...

If you are interested in the US market and looks for blessing in disguise counter and of cause if u hv USD$$ in plenty, below five companies make swine flu vaccine for the U.S. market:

1) AstraZeneca's
[AZN 46.16 -0.14 (-0.3%) ]
2) MedImmune unit, CSL
3) GlaxoSmithKline
[GSK 39.44 -0.59 (-1.47%) ]
4) Novartis
[NVS 45.30 -0.19 (-0.42%) ]
5) Sanofi-Aventis
[SNY 33.94 0.06 (+0.18%) ]

.
CSL and Sanofi have started U.S. trials and several companies, including Glaxo, have trials ongoing in Europe. The U.S. Food and Drug Administration will license the new vaccine as a "strain change" from seasonal influenza — treating it as the usual annual reformulation of the annual flu vaccine.
Pandemic H1N1 is circulating widely and experts expect it to get worse in the Northern Hemisphere's fall as schools get under way. The council's report says the virus, although moderate, poses a serious health threat to the United States because it is likely to infect so many people.
(source : CNBC)
...